ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1129

Tumor Necrosis Factor Receptor 2 Is Crucial for Regulatory T Cells Activity with Consequences in a Model of Chronic Inflammation and in Anti-TNF Treated Rheumatoid Arthritis

Francois Santinon1, Maxime Batignes1, Magali Breckler1, Roxane Herve1, Fredéric Caux1,2, Patrice Decker3, Marie-Christophe Boissier1,4, Luca Semerano1,4 and Natacha Bessis5, 1INSERM UMR 1125 University of Paris 13, Sorbonne Paris Cité, bobigny, France, 2Dermatology Dpt, Avicenne teaching Hospital, APHP, bobigny, France, 3UMR 1125, Inserm, Bobigny, France, 4Rheumatology Dpt, Avicenne teaching Hospital, APHP, bobigny, France, 5INSERM UMR 1125 University of Paris 13, Sorbonne Paris Cité, Bobigny, France

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: T-Regulatory Cells and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: CD4+FoxP3+ regulatory T cells (Tregs) are essential for maintaining immune homeostasis, and are functionally defective in rheumatoid arthritis (RA) and other chronic inflammatory diseases. In RA, effective anti-TNF treatment was found to modify Tregs phenotype and restore their suppressive function. Tregs express the two TNF receptors (TNFR): TNFR1 and TNFR2. Nevertheless, the respective roles of TNFR1 and TNFR2 in mediating the effect TNF on Tregs are still unclear. Likewise, whether TNF blockade may affect Tregs via the TNF receptors, is not clearly established.  To dissect the role of the TNF-TNFR2 system on Tregs in chronic inflammatory diseases by : 1) determining the effect of the interaction between TNF and TNFR2 on cultured mouse Tregs 2) studying the effect of TNFR2 deficiency in a model of chronic inflammation 3) analyzing the influence of anti-TNF therapy on TNFR2 expression on Tregs in RA patients

Methods: Tregs were purified by magnetic separation from mice spleen and their frequencies and phenotype were analyzed by flow cytometry. TNFR2 deficient mice were used. Psoriasis-like skin inflammation was induced by imiquimod skin application. Tregs from blood of RA patients were studied by flow cytometry.

Results: TNF induces Foxp3 maintenance in cultures of purified mouse Tregs. With two models of TNFR2 inactivation (a TNFR2-blocking antibody and a TNFR2 knock-out mouse) we showed that this effect was mediated by TNF-TNFR2 -and not TNFR1- interaction. Moreover, compared to Tregs from wild type (WT) mice, TNFR2-deficient Treg showed reduced suppression of effector T cells (Teff) proliferation and Teff interferon-g production. TNF decreased CD39 expression and ATP hydrolysis activity in cultured Tregs. Additionally, TNFR2-deficient Tregs were less effective in hydrolyzing ATP than Tregs from WT mice. In parallel, we evaluated the consequences of TNFR2 deficiency in a model of skin inflammation, namely imiquimod-induced psoriasis. In TNFR2- deficient mice, Tregs frequencies were lower and the clinical signs of psoriasis were aggravated, compared to WT mice. Moreover, in the peripheral blood of RA patients treated with anti-TNF agents there was both an increase in total Tregs frequencies, and in the frequency of Tregs expressing TNFR2 at 3 months of treatment vs. the baseline.

Conclusion: The integrity of the TNF-TNFR2 system is critical for Treg survival and suppressive activity  in vitro. TNFR2 deficiency aggravates a model of chronic skin inflammation. Three-month anti-TNF treatment is associated with an increase of TNFR2-expressing Tregs in the peripheral blood of RA patients. These data suggest that the effect of TNF blockade on Tregs may rely on the activation of the TNF-TNFR2 system.


Disclosure: F. Santinon, None; M. Batignes, None; M. Breckler, None; R. Herve, None; F. Caux, None; P. Decker, None; M. C. Boissier, None; L. Semerano, None; N. Bessis, None.

To cite this abstract in AMA style:

Santinon F, Batignes M, Breckler M, Herve R, Caux F, Decker P, Boissier MC, Semerano L, Bessis N. Tumor Necrosis Factor Receptor 2 Is Crucial for Regulatory T Cells Activity with Consequences in a Model of Chronic Inflammation and in Anti-TNF Treated Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/tumor-necrosis-factor-receptor-2-is-crucial-for-regulatory-t-cells-activity-with-consequences-in-a-model-of-chronic-inflammation-and-in-anti-tnf-treated-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tumor-necrosis-factor-receptor-2-is-crucial-for-regulatory-t-cells-activity-with-consequences-in-a-model-of-chronic-inflammation-and-in-anti-tnf-treated-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology